Aeglea BioTherapeutics, Inc. (AGLE)
(Delayed Data from NSDQ)
$6.96 USD
+0.24 (3.57%)
Updated May 3, 2019 04:00 PM ET
After-Market: $6.94 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$6.96 USD
+0.24 (3.57%)
Updated May 3, 2019 04:00 PM ET
After-Market: $6.94 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
AstraZeneca (AZN) Q1 Earnings Beat, Revenues Meet Estimates
by Zacks Equity Research
AstraZeneca PLC (AZN) reported first-quarter 2017 core earnings of 99 cents per American Depositary Share, which comfortably beat the Zacks Consensus Estimate of 38 cents.
Should You Get Rid of Incyte Corporation (INCY) Now?
by Zacks Equity Research
Investors may consider dropping the Zacks Rank #4 Incyte Corporation (INCY) stock, which has witnessed a significant price decline in the past four weeks, and it has seen negative earnings estimate revisions for the current quarter and the current year.
Arena Pharma (ARNA) Down After Underwritten Public Offering
by Zacks Equity Research
Arena Pharmaceuticals, Inc.'s (ARNA) shares dropped more than 13% on Apr 18, after the company announced that it will be raising funds through an underwritten public offering.
Rigel Pharmaceuticals Files NDA for Thrombocytopenia Drug
by Zacks Equity Research
Rigel Pharmaceuticals, Inc. (RIGL) recently announced that it has filed a new drug application (NDA) to the FDA, for its oral spleen tyrosine kinase inhibitor, fostamatinib for the treatment immune thrombocytopenia (ITP).
Aeglea Biotherapeutics (AGLE) Looks Good: Stock Jumps 7%
by Zacks Equity Research
Aeglea Biotherapeutics, Inc. (AGLE) shares rose over 7% in the last trading session.
Aeglea Biotherapeutics (AGLE) Enters Oversold Territory
by Zacks Equity Research
Aeglea Biotherapeutics, Inc. (AGLE) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock